Media Experts
Cancer, drug discovery
Timothy Ratliff, the Robert Wallace Miller Director of the Purdue University Center for Cancer Research, can talk about cancer research, treatments, diagnostics and the future direction of cancer treatment and prevention.
The center is one of seven National Cancer Institute-designated basic science cancer centers in the nation. Ratliff is nationally recognized for his achievements in urologic cancer research and was a member of the team that developed the prostate-specific antigen test, or PSA, which, in combination with a digital exam, is the most-used test to detect prostate cancer. As the center’s director he oversees discovery groups working on cancers of the bladder, brain, breast, and prostate, as well as obesity and cancer. The center has collaborations with the Indiana University Melvin and Bren Simon Cancer Center in Indianapolis and IU Health Arnett in Lafayette, Indiana. It is a member of The Big Ten Cancer Research Consortium.
Ratliff can discuss:
- Trends in cancer research and treatment
- The importance of cancer screening tests
- The path from potential drug discovery to treatment
- Breast cancer, brain cancer, bladder cancer, and prostate cancer
- Advances in the study of cancer prevention
- The role of obesity in cancer development and progression
- His personal inspiration to pursue cancer research
- The Prostate-Specific Antigen test (PSA test)
- Immunotherapy of cancer
Contact: Timothy Ratliff, 765-494-9129,tlratliff@purdue.edu
Professor Ratliff’s related news releases:
- National Cancer Institute renews designation for Purdue center, awards $8 million
- Purdue-IU team uncovers potential prostate cancer marker
- Purdue takes prostate cancer treatment from concept to clinical trial
- Purdue to accelerate drug discovery, development
- With new year comes new resolve in fight against cancer